111 matches.
- BlogsCMS Rules Propose Changes Regarding the Medicare Prescription Drug Inflation Rebate Program, Refundable Drugs, Skin Supplements and More; Comments Due September 913 minute read
- BlogsLast Call for Comments on the Bipartisan Discussion Draft of the SUSTAIN Act: Shaping 340B for the Future10 minute read
- EventsRx Drug Pricing Boot Camp: An In-Depth Look at the Effects of the Genesis Case1 minute read
- EventsImplications of the Genesis Federal Court Decision on 340B Patient Definition2 minute read
- PublicationsIn Genesis Case, South Carolina District Court Scraps HRSA Interpretation of “Patient” Under 340B Statute9 minute read
- Media CoverageConnie Wilkinson Quoted in “Stelara Biosimilar Tests Market Impact of Drug Price Program”3 minute read
- PublicationsCMS Seeks Stakeholder Feedback About Medicare Transaction Facilitator Services for the Medicare Drug Price Negotiation Program by November 13: Inflation Reduction Act Updates4 minute read
- EventsPharmaceutical and Medical Device Ethics and Compliance Congress: Drug Pricing—Considerations Around Price Controls, Negotiation, and Access1 minute read
Game-Changing IRA: Revolutionizing Prescription Drug Pricing and Medicare Benefits- BlogsCMS Names Its First Ten Negotiated Part D Drugs: Inflation Reduction Act Updates11 minute read
- PublicationsState Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of Oklahoma PBM Law25 minute read
Inflation Reduction Act’s Drug Price Negotiation Provisions – What Now?- PublicationsCMS Releases Its List of 43 Part B Rebatable Drugs for Q3: Inflation Reduction Act Updates7 minute read
- PublicationsManufacturers Must Request Small Biotech Exception by July 3: Inflation Reduction Act Updates4 minute read
- PublicationsCMS Seeks Comment on Initial Guidance for the Part D Manufacturer Discount Program: Inflation Reduction Act Updates2 minute read
- BlogsMore Federal Action in the Pharmaceutical Sector as PBM Bill Advances in the Senate12 minute read
- EventsMedicaid and Government Pricing Congress2 minute read
- EventsRx Drug Pricing Boot Camp: A Look into the Seismic Impact of Litigation on the 340B Drug Pricing Program1 minute read
-
Inflation Reduction Act’s Drug Price Negotiation Provisions – What’s Next?
- PublicationsCMS Issues an Information Collection Request for the Drug Price Negotiation Process: Inflation Reduction Act Updates3 minute read
- PublicationsCMS’s Initial Guidance on Medicare Drug Price Negotiation Program Suggests Familiar Pharmacy Chargeback Process12 minute read
- PublicationsCMS Issues an Information Collection Request on Negotiation Data Elements: Inflation Reduction Act Updates3 minute read
- PublicationsCMS Issues New Guidance on Medicare Drug Price Negotiation Program: Inflation Reduction Act Updates2 minute read
- PublicationsCMS Releases Its List of 27 Part B Rebatable Drugs for Q2 of 2023: Inflation Reduction Act Updates3 minute read
- BlogsComments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 202310 minute read
- PublicationsCMS Launches First Federal Regulatory Action to Implement Medicare Drug Price Negotiation Program6 minute read
- EventsInflation Reduction Act: Win, Lose or Draw for Stakeholders2 minute read
- PublicationsMore Changes in Store for Pharmaceutical Supply Chain Following Passage of Inflation Reduction Act18 minute read
- PublicationsFTC’s PBM Study Signals Broader Federal Scrutiny of the Prescription Drug Sector23 minute read
- PublicationsCMS Finalizes Changes to Pharmacy DIR in Part D Starting with Contract Year 202414 minute read
-
President Biden’s Use of the Defense Production Act
- EventsOppenheimer 31st Annual Healthcare Conference1 minute read
- BlogsPresident Biden Revokes Trump Administration’s Workplace Diversity Training Restrictions2 minute read
- PublicationsFinalized HHS Drug Formulary Rebate Rule Faces Uncertain Future Under Biden Administration and Current Legal Challenge20 minute read
- EventsWhat’s Next for Medicaid? Innovation Is Blurring Boundaries, Driving Value and Challenging the Status Quo1 minute read
- BlogsNAACP Lays Down First Challenge to Executive Order 13950 Prohibiting Inclusion of “Divisive” Concepts in Workplace Training Programs3 minute read
- PublicationsExecutive Order Prohibits Inclusion of "Divisive" Concepts in Workplace Training11 minute read
- PublicationsPresident Trump Signs Executive Orders on Drug Pricing and Domestic Supply Chain Reform22 minute read
- PublicationsChapter 6, "Federal Health Care Programs: Coverage and Reimbursement of Prescription Drugs and Medical Devices"2 minute read
- EventsNEHI: Next Generation Therapies - What's Next?1 minute read
- EventsBona Fide Service Fees and Fair Market Value Determination1 minute read
- EventsHHS OIG Proposed Rule on the Safe Harbor for Pharmaceutical Rebates: The Issues and Impact2 minute read
- EventsDrug Pricing and Reimbursement: 2018 in Review and Outlook for 20192 minute read
- PublicationsHHS OIG Proposes Anti-Kickback Safe Harbor Amendments to Regulate and Restrict the Provision of Manufacturer Remuneration to Plan Sponsors and PBMs19 minute read
- PublicationsCMS Releases Medicare Advantage and Part D Drug Pricing Proposed Rule for Contract Year 202028 minute read
- BlogsHRSA Establishes January 1, 2019 Effective Date for 340B Ceiling Price and Civil Monetary Penalty Rule3 minute read
- BlogsCMS Seeks to Revamp Medicare Part B Drug Reimbursement through Proposed International Pricing Index (IPI) Model3 minute read
- EventsMedicaid Drug Rebate Program: Role of Reimbursement Reform and Drug Pricing - Federal Level1 minute read
- BlogsCMS Finalizes Policy and Technical Changes to the Medicare Advantage and Part D Programs for CY 20195 minute read
- BlogsWhite House 2019 Budget and White Paper Shape Ambitious Policy to Reduce Drug Prices8 minute read
-
Trends in TRICARE: Thought Leaders in Health Law Video Series
- PublicationsComment Deadline Approaches for CMS's Proposed Changes to Medicare Advantage and Part D Programs for CY 2019 – Part 2: Beneficiary Cost, Access, and Protection21 minute read
- PublicationsComment Deadline Approaches for CMS's Proposed Changes to Medicare Advantage and Part D Programs for CY 2019 - Part 1: Negotiated Prices for Drugs15 minute read
- PublicationsComment Deadline Approaches for CMS's Proposed Changes to Medicare Advantage and Part D Programs for CY 2019 – Part 3: Part D Drug Management Programs Following Adoption of the Comprehensive Addiction and Recovery Act13 minute read
- BlogsCMS Final Rule Will Reduce Medicare Part B Drug Payments by Nearly 30% for 340B Hospitals5 minute read
- Media CoverageConstance Wilkinson Quoted in "Top Four Approaches to Reduce Pharmaceutical Costs"2 minute read
-
Trends in Drug Pricing and Reimbursement: Thought Leaders in Health Law Video Series
- EventsManufacturers' 340B Summit: "Specialty Pharmacy" and "Hot Topics Round Up"1 minute read
Career Pathways: Attorney Connie Wilkinson, Part 2 - Flexible Schedule-
Career Pathways: Attorney Connie Wilkinson, Part 1: A Collegial Environment
- EventsThe Effect of the Average Manufacturer Price Final Rule on Drug Pricing and Contracting, Part 1: The Impact of the AMP Final Rule: Legal, Operational, and Financial Considerations3 minute read
- EventsManaged Markets & Payer Marketing Strategies Conference: Regulatory Breakdown - Reviewing the AMP Final Rule1 minute read
- Media CoverageConstance Wilkinson Quoted in "Long-Awaited AMP Rule Heralds Shift to Acquisition Cost-Based Reimbursement"2 minute read
- PublicationsCMS Issues Final Rule on Covered Outpatient Drugs38 minute read
- PublicationsOpportunities in Connected Health: Improving Patient Care, Reducing Provider Cost, and Enabling New Business Models2 minute read
- BlogsU.S. District Court Vacates HRSA's Interpretative Rule on Orphan Drugs9 minute read
- Events2015 MDRP Summit: Addressing Key Areas Covered Within the 340B "Omnibus Guidance"1 minute read
- BlogsHRSA Issues Proposed "Omnibus Guidance"11 minute read
- PublicationsHouse Energy and Commerce Committee Proposes, then Drops, 340B Reform Language to 21st Century Cures Legislation1 minute read
- BlogsHouse Energy and Commerce Committee Proposes, then Drops, 340B Reform Language to 21st Century Cures Legislation4 minute read
- PublicationsConstance Wilkinson, Alan Arville Comment on Specialty Drug Cost Upswing2 minute read
- PublicationsLegal Risks of Co-Payment Assistance Programs2 minute read
- PublicationsVeterans Choice Program Expanded in Interim Final Rule by the Department of Veterans Affairs12 minute read
- BlogsHRSA Withdraws 340B "Mega-Reg;" Plans to Issue Guidance in 20156 minute read
- PublicationsOPM Issues Ebola Guidance to FEHBP Carriers1 minute read
- BlogsOPM Issues Ebola Guidance to FEHBP Carriers3 minute read
- PublicationsOIG Warns Pharmaceutical Manufacturers of Improper Part D Beneficiary Coupon Use9 minute read
- BlogsHRSA Issues Interpretive Rule on 340b Orphan Drug in Response to Court Vacating Final Rule7 minute read
- PublicationsMore of the Same: Recently Released FDA Social Media Guidance for the Life Sciences Industry13 minute read
- EventsWorld Congress Executive Forum on Managed Care Strategies in the New Health Economy: The Evolving Landscape of the 340B Program - Update on Oversight, Regulation, Program Integrity, and Recent Developments1 minute read
- EventsACI's "Big Four" Pharmaceutical Pricing Boot Camp: What to Expect When You're Expecting an FSS Contract: A Practical Guide1 minute read
- PublicationsMore Contract Pharmacy Oversight for HHS 340B Program, inLaw3602 minute read
- BlogsOIG Issues Report on 340B Contract Pharmacy Arrangements Supporting Need for Tighter Rules6 minute read
- PublicationsThe Expansion of Federal Subcontractor Status to Health Care Providers, in Public Contract Law Journal2 minute read
- Firm AnnouncementsConstance Wilkinson Recognized as a "Life Science Star" by LMG Life Sciences1 minute read
- Firm AnnouncementsEpstein Becker Green Promotes 13 Attorneys in Four Practices - Health Care and Life Sciences, Labor and Employment, Litigation, and Corporate Services3 minute read
- EventsCorporate Integrity Agreements and Corporate Compliance Programs1 minute read
- Events17th Annual Medicaid Drug Rebate Program Summit1 minute read
- Firm AnnouncementsThree Epstein Becker Green Attorneys Recognized as Life Science Stars by LMG Life Sciences1 minute read
- PublicationsHEALTH REFORM: CMS Issues Proposed Rule Relating to Manufacturer Rebates and Reimbursement Amounts for Outpatient Prescription Drugs Dispensed to Medicaid Beneficiaries2 minute read
- Events16th Annual Summit on the Medicaid Drug Rebate Program & Other Public Sector Reimbursement Programs1 minute read
- PublicationsHEALTH REFORM: OPM RFI Regarding Multi-State/National Insurance Plans10 minute read
- EventsAmerican Conference Institute's 7th National Drug Pricing Boot Camp1 minute read
- EventsACI's 5th Annual "Big Four" Pharmaceutical Pricing Boot Camp3 minute read
- PublicationsWhat Will Fill the "Donut Hole"? A Summary of the Medicare Part D Coverage Gap Discount Program, as appeared in AHLA Life Sciences1 minute read
- PublicationsRecent Developments in the Federal Prescription Drug Pricing Programs21 minute read
- Events15th Annual Summit on the Medicaid Drug Rebate Program & Other Public Sector Reimbursement Programs1 minute read
- PublicationsHEALTH REFORM: CMS Proposes to Withdraw Regulations on Average Manufacturer Price Determination, Multiple Source Drug Definition, and Medicaid Federal Upper Limits10 minute read
- EventsChanges to the Medicaid Drug Rebate and Section 340B Discount Drug Programs: A Practical Approach to Understanding What Health Reform Means, What to Do and by When3 minute read
- PublicationsHEALTH REFORM: Medicaid Drug Rebate Program 'Reform': Key Considerations and Implementation Tips for Pharmaceutical and Biotech Manufacturers14 minute read
- PublicationsHRSA Finally Publishes Final Contract Pharmacy Guidelines For 340B Program6 minute read
- PublicationsTop Ten Key Issues Concerning "Biosimilars"13 minute read
- PublicationsThe Proposed Approval Pathway for "Biosimilars" and Its Potential Implications for Various Stakeholders17 minute read
- EventsIIR's 14th Annual Summit on the Medicaid Drug Rebate Program2 minute read
- EventsLabor & Employment Women Executives Networking Briefing: OFCCP, Federal Contractors & The Obama Administration: The New Compliance Requirements3 minute read
- Events13th Annual Summit on the Medicaid Drug Rebate Program & Other Public Sector Reimbursement Programs1 minute read
- EventsIIR's MDRP 101 Conference1 minute read
- PublicationsSPECIAL ALERT: CMS Issues Final Rule Relating to Medicaid Payments For Outpatient Prescription Drugs1 minute read
- EventsAmerican Health Quality Association 2007 Annual Meeting -- "Making A Difference"!1 minute read
- EventsCBI's 4th Annual Pharmaceutical Marketing Compliance Congress1 minute read
- PublicationsGovernment Contracting and the War on Terrorism New Opportunities, New Perils1 minute read
